**Gavin J Becker, MD, FRACP (Work Group Co-Chair)**, is Professor and Director of Nephrology at the Royal Melbourne Hospital and Clinical Director of Renal and Endocrinology Services at Melbourne Health. He maintains an active role in numerous professional societies including serving as a current member of the International Society of Nephrology (ISN) Executive Committee, Cochrane Renal Collaboration Advisory Board and Co-Chair of the World Health Organization ICD-11Renal Diseases Working Group. He is a Past President of the Asian Pacific Society of Nephrology. Dr Becker has published over 300 papers, chapters and books and presently serves as Associate Editor for *Nephrology Dialysis Transplantation*. He has served as Editor of *Nephrology*, Associate Editor or on the editorial boards of the *Journal of the American Society of Nephrology*, *Clinical Journal of the American Society of Nephrology*, *American Journal of Kidney Diseases*, *Nephron*, and *Journal of Nephrology*. His research interests center on the progression of kidney failure, development of guidelines for renal care, promotion of renal physician education and the development of nephrology in the Asian Pacific region. In recognition for his work, he was awarded the International Distinguished Medal by the US National Kidney Foundation in 2002. He was also a recipient of an Honorary Fellowship of the Ceylon College of Physicians in 2003, the Oshima Award from the Asian Pacific Society of Nephrology in 2005 and Chairman\'s 'Best of Health\' Award from Melbourne Health in 2002 and again in 2009.

*Dr Becker reported no relevant financial relationships*

**David C Wheeler, MD, FRCP (Work Group Co-Chair)**, holds an academic position in Nephrology (Reader) at University College London, UK and is an Honorary Consultant Nephrologist at the Royal Free Hospital. His research is focused on the cardiovascular complications of CKD and the role of vascular risk factors in progression of kidney damage. Dr Wheeler is a member of the International Steering Committee of the Study of Heart and Renal Protection (SHARP) and was UK National Coordinator for the trial. He is involved in several other randomized trials and observational studies involving patients with CKD.

Dr Wheeler is Co-Chair of KDIGO, having served previously on its Executive Committee and Board. He received an International Distinguished Medal from the US National Kidney Foundation in recognition of his contribution to guideline development. In the UK, he has been elected President of the Renal Association for the term 2012--2014.

Dr Wheeler has served on the editorial boards of *American Journal of Kidney Diseases* and *Journal of the American Society of Nephrology* and is presently Co-Editor for *Nephrology Dialysis Transplantation*.

*Advisor/Consultant: Amgen*

*Honoraria: Abbott; Amgen; Fresenius; Otsuka; Shire*

*Travel Stipend: Amgen; Merck Sharp & Dohme; Shire*

*Grant/Research Support: Abbott; Genzyme*

**Dick de Zeeuw, MD, PhD**, earned his MD from the University of Groningen in 1975. He completed his PhD thesis in 1980 on the topic of renal hypertension at the Renal Department of the Groningen University. He later obtained training in clinical and experimental renal research at the Renal Department in Groningen and clinical pharmacology at the University of Dallas (1984--1985) and was board certified in 1996 at the University of Groningen. Dr de Zeeuw is currently Professor and Chair of the Department of Clinical Pharmacology with a joint appointment in the Department of Nephrology. He has served on the editorial board of several international journals, including *Clinical Nephrology*, *Current Opinion in Nephrology and Hypertension, Journal of Geriatric Urology and Nephrology, Journal of Hypertension*, *Journal of the Renin-Angiotensin-Aldosterone System*, *Kidney International*, *NDT Plus*, and *Nephron.*

Dr de Zeeuw is Director of the Groningen University Institute for Drug Exploration (GUIDE), and member of ISN Council. His research interests include: optimizing current therapies and finding new therapeutical approaches to reduce the progressive loss of cardiovascular and renal function, both in diabetic and non-diabetic renal disease. The role of albuminuria/proteinuria and microalbuminuria as biomarkers for cardiac and renal disease progression has been his particular interest, not only in trying to establish the independent 'causal\' role of albumin leakage in renal and CVD progression, but also to establish intervention strategies that lower albuminuria/proteinuria with the supposed organ protective results. In his 'albuminuria\' quest he initiated large cohort studies such as PREVEND (in general population) and GIANTT (type 2 diabetes), and is involved in the leadership of several clinical trials on preventing diabetic cardiovascular and renal disease progression such as RENAAL (angiotensin II receptor antagonist), PLANET (statin), TREAT (darbepoetin), VITAL (vitamin D), SUN (sulodexide), ALTITUDE (renin-inhibition), CANVAS (SGLT2-inhibition), RADAR (atrasentan) and BEACON (bardoxolone).

Unraveling the reasons for individual therapy resistance and creating a response score to evaluate the total effect of drugs are the topics that he judges to be of important focus for the next decade. He has authored more than 440 international scientific publications and more than 60 book chapters, and received the Lennart Hansson Memorial Lecture Award from the European Society of Hypertension, the International Distinguished Medal from the US National Kidney Foundation, and a special lecture award from the Japanese Society of Nephrology.

*Advisor/Consultant: Abbott; Amgen; Astellas; AstraZeneca; Bristol-Myers Squibb; HemoCue; Johnson & Johnson; Merck Sharp & Dohme; Novartis; Reata; Takeda; Vitae*

**Toshiro Fujita, MD**, is Professor and Chairman of the Department of Internal Medicine and Chief of the Department of Nephrology and Endocrinology at the University of Tokyo. He qualified in medicine in 1972 at the Keio University School of Medicine, Japan and remained in Keio until 1976, during which time he completed his medical internship and residency. Between 1976 and 1978, he was a Research and Clinical Fellow at National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA. Upon his return to Japan, he was appointed Assistant Professor of Internal Medicine, firstly at the University of Tsukuba and later at the University of Tokyo School of Medicine. Since 1995, Professor Fujita has been Chairman of the Department of Internal Medicine at the Graduate School of Medicine and Faculty of Medicine, University of Tokyo, and is Chief of the Department of Nephrology and Endocrinology at the University of Tokyo Hospital.

In 1980, Fujita and Bartter at NIH demonstrated the pathophysiology of salt-sensitive hypertension (*Am J Med 1980*). Since then, he has been continuing research on renal and metabolic aspects of hypertension. His research interests include nephrology, endocrinology, metabolic science and cardioangiology. Dr Fujita\'s group has reported the involvement of aldosterone/mineralocorticoid receptor (MR) activation in salt-sensitive hypertension and metabolic syndrome. Recently, they found an alternative pathway of MR activation: modification of MR function by Rac1 GTPase (*Nat Med 2008*). Most recently, his group clarified the involvement of aberrant renal β adrenergic receptor-WNK4 pathway in salt-induced hypertension (*Nat Med 2011*).

A renowned expert in his field, Professor Fujita has been actively contributing to professional associations and scientific publications and his contribution to the study of hypertension and kidney diseases has been widely recognized. In 2009, Professor Fujita was awarded Arthur Corcoran Lecture Award by the Council for High Blood Pressure Research, American Heart Association (AHA). Over the past 30 years, Professor Fujita has published over 500 scientific articles and has been a member of the Committee of the High Blood Pressure Council, AHA. Professor Fujita is currently serving as a Consulting Editor for *Hypertension* and an Editorial Board member for *Diabetes*. He was Past President of the Japanese Society of Hypertension (2003--2005), the Japanese Society of Internal Medicine (2004--2006), the Japanese Society of Endocrinology (2006--2007), and the Japanese Society of Nephrology (2009--2010). He was also Vice-President, International Society of Hypertension (2008--2010).

*Speaker: Astellas; Boehringer Ingelheim; Daiichi Sankyo; Merck; Mitsubishi Tanabe; Mochida; Novartis; Pfizer; Takeda*

*Grant/Research Support: Astellas; Boehringer Ingelheim; Daiichi Sankyo; Merck; Mitsubishi Tanabe; Mochida; Novartis; Pfizer; Takeda*

**Susan L Furth, MD, PhD**, is Chief, Divison of Pediatric Nephrology at Children\'s Hospital of Philadelphia and Professor, Department of Pediatrics and Epidemiology, Perelman School of Medicine at University of Pennsylvania School of Medicine, where she is also currently a Senior Scholar and faculty member at the institution\'s Center for Clinical Epidemiology and Biostatistics. Dr Furth received her medical degree from University of Pennsylvania and doctorate degree from Johns Hopkins University School of Hygiene and Public Health. She maintains a longstanding interest in the studies of children and adolescents with kidney disease, particularly their risk factors and consequences, including pediatric hypertension. As Principal Investigator of CKiD, she directs a multidisciplinary team for one of the largest multicenter, prospective cohort studies of children with CKD to better identify risk factors for CKD progression, neurocognitive deficits and CVD. Dr Furth is also a recipient of an National Institute of Diabetes and Digestive and Kidney Diseases Investigator Award in Clinical Research to mentor fellows and junior faculty on the evaluation of hypertension and risk of kidney dysfunction using national pediatric data.

In addition to being a peer reviewer for 20 academic journals, Dr Furth has authored over 100 publications and served as a thesis advisor to more than 30 students. As an acknowledgment for her contribution, Dr Furth was awarded 'Pediatric Leaders for the 21st Century\' by the American Society of Pediatric Nephrology and American Academy of Pediatrics and is currently President of the Society for Pediatric Research.

*Dr Furth reported no relevant financial relationships*

**Hallvard Holdaas, MD, PhD**, is senior consultant in Nephrology at Department of Transplant Medicine, Oslo University Hospital, Rikshospitalet, Norway, where he also received his training in transplant medicine. His primary research interests are immunosuppression, dyslipidemia, and CVD in renal transplant recipients. He was the principal investigator in the ALERT trial (fluvastatin) and co-investigator in the AURORA and SHARP trials.

Dr Holdaas is a member of numerous professional organizations including American Society of Nephrology, American Society of Transplantation, European Dialysis and Transplant Association and European Society for Organ Transplantation. He has published more than 170 original articles, reviews and book chapters in the fields of nephrology, dialysis and transplantation.

*Advisor/Consultant: Merck (Schering Plough); Novartis;*

*Speaker: AstraZeneca; Bristol-Myers Squibb; Novartis*

**Shanthi Mendis, MBBS, MD, FRCP, FACC**, is Senior Advisor for Cardiovascular Diseases and Coordinator, Chronic Disease Prevention and Management at the World Health Organization (WHO) in Geneva, Switzerland. Prior to taking up the position in WHO, she was Professor of Medicine at Peradeniya Medical School in Sri Lanka from 1991--2000. As a specialist in cardiology and public health with expertise in policy development, she has written extensively on the prevention and management of CVD in a global context. In particular, she has advocated for the development of national policies and strategies to combat non-communicable diseases which strike disproportionately in low- and middle-income countries.

*Dr Mendis reported no relevant financial relationships*

**Suzanne Oparil, MD**, is Professor of Medicine, Professor of Cell, Developmental and Integrative Biology, and Physiology & Biophysics, and Director of the Vascular Biology and Hypertension Program of the Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham. She earned her medical degree at Columbia University College of Physicians and Surgeons, New York and completed her medical residency at Columbia Presbyterian Hospital and cardiology fellowship at Massachusetts General Hospital. Dr Oparil is Past President of the American Heart Association (AHA) and American Society of Hypertension, and a member of numerous editorial boards, societies and important advisory positions with the NIH (Co-Chair, JNC 8). She has published over 700 journal articles, books, and book chapters on topics in clinical cardiology, vascular biology and hypertension. Dr Oparil has received a number of honorary memberships, lectureships, and distinguished awards for her contributions to hypertension research, including the Irving Page-Alva Bradley Lifetime Achievement Award, given by the AHA Council for High Blood Pressure Research (2002); the 2008 Harriet Dustan Award, sponsored by the AHA Council for High Blood Pressure Research; the Virginia Frantz '22 Award for Distinguished Women in Medicine (2010) presented by Columbia University College of Physicians and Surgeons; and the ICS Distinguished Lecture Award (2011), sponsored by the Institute of Cardiovascular Sciences.

Dr Oparil is a cardiologist with a special interest in the fundamental mechanisms of CVD and in applying this information to the development of novel treatments. Her research ranges from molecular and cellular studies to whole animal studies to clinical trials. She has made a number of innovative discoveries with major clinical impact: 1) observing that angiotensin-converting enzyme (ACE) is involved in vascular disease, leading to the development of ACE-Is; 2) identifying endothelin as the major mediator of pulmonary hypertension and pulmonary vascular disease, leading to the development of a class of drugs for patients with pulmonary hypertension; and 3) defining novel pathways by which blood vessels are protected from injury by estrogens, providing crucial information on potential targets for future gene therapy. She has made many significant contributions to vascular biology and hypertension research.

*Advisor/Consultant: BackBeat Medical; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Eli Lilly; Forest Laboratories; Medtronic; Merck; NicOx; Novartis;Omron Healthcare; Pfizer*

*Grant/Research Support: Daiichi Sankyo; Merck; Novartis; Takeda*

**Vlado Perkovic, MBBS, FRACP, FASN, PhD**, is Executive Director, George Clinical at The George Institute for International Health and Staff Specialist in Nephrology and Hypertension at the Royal North Shore and Sydney Adventist Hospitals. Dr Perkovic received his medical and doctorate degrees from University of Melbourne and completed his training in nephrology and general medicine at the Royal Melbourne Hospital. His research interests include elucidating the roles of BP and lipid management and their impact on CVD in CKD patients. In this vein, Dr Perkovic is a committee member of the ALTITUDE and SHARP trials and an organizer of the Cardiovascular Guideline Group for Caring for Australasians with Renal Impairment (CARI). As an author of over 75 publications, Dr Perkovic also serves as a peer reviewer to numerous journals and a grant reviewer for the National Health and Medical Research Council.

*Advisor/Consultant: Abbott; Baxter; Boehringer Ingelheim; Johnson & Johnson; Vitae*

*Honoraria: AstraZeneca; Roche; Servier*

*Grant/Research Support: Baxter; Johnson & Johnson*

**Cibele Isaac Saad Rodrigues, MD, PhD**, is a full Professor of Nephrology at the Faculdade de Ciências Médicas e da Saúde -- Pontifícia Universidade Católica de São Paulo -- (PUC-SP), Brazil where she also graduated and completed her Residency in Internal Medicine and Nephrology. She obtained her master\'s and doctorate degrees in Nephrology at the Federal University of São Paulo, Brazil. Currently she is the academic coordinator of Santa Lucinda Hospital in Sorocaba--São Paulo, coordinator of the Hypertension Department of the Brazilian Society of Nephrology, and member of the Scientific Council of the Brazilian Society of Hypertension. From 2001 to 2009 she was the dean of the Centro de Ciências Médicas e Biológicas (PUC-SP) and President of the Administration Council of Santa Lucinda Hospital. Her primary research interests are hypertension, diabetic nephropathy and CKD. Professor Rodrigues has published more than 40 journal articles and contributed 15 book chapters in the field of nephrology and hypertension. She is a member of numerous professional organizations in Brazil and abroad, and has served as peer reviewer for many scientific journals and an advisory committee member to various organizations.

*Dr Rodrigues reported no relevant financial relationships*

**Mark J Sarnak, MD, MS,** is Professor of Medicine at Tufts University of School of Medicine in Boston, Massachusetts, USA and Director of Research in the Division of Nephrology at Tufts Medical Center. He obtained his medical degree from Columbia University College of Physicians and Surgeons and master′s degree in clinical care research from Tufts University of Medicine. His current research encompasses various topics including the role of aging in CKD, the relationship between cognition and CKD, and CVD in CKD. He has lectured extensively on the epidemiology and management of traditional and non-traditional cardiovascular risk factors in CKD. Dr Sarnak has authored more than 175 publications and is a peer reviewer for more than a dozen journals. He was Co-Editor for *American Journal of Kidney Disease* between 2006--2007 and presently serves on the Editorial Board of the *Annals of Internal Medicine*. Among the recent honors he has received include Best Teacher Award for the Medical Residents in 2008, Excellence in Teaching in the Medical Clerkship in 2009, and an acknowledgment in Boston Magazine Best Doctors in both 2010 and 2011.

*Dr Sarnak reported no relevant financial relationships*

**Guntram Schernthaner, MD**, became Professor of Medicine at the University of Vienna, Austria in 1987. Since 1988 he has been Head of the Department of Medicine I at the Rudolfstiftung Hospital in Vienna and between 1982 and 1988 he served as Head of the Division of Metabolism & Endocrinology at the University of Vienna. Professor Schernthaner\'s main research interests are diabetes mellitus (including diabetic nephropathy, diabetic retinopathy, insulin resistance, CVD, hemostasis, immunotherapy of type 1 diabetes, gestational diabetes), hypertension and morbid obesity.

Professor Schernthaner has held various prestigious positions, including serving as Council Member and Vice-President of the European Society for Clinical Investigation; President of the Austrian Diabetes Association; President of the first Joint Congress of the German and Austrian Diabetes Associations; Council Member of the European Diabetes Association; and President of the 32nd European Diabetes Congress (EASD, Vienna 1996).

Professor Schernthaner has authored more than 350 publications in peer-reviewed journals and has presented invited lectures at many international congresses, symposia and universities in more than 50 countries. According to the Citation Index of Web of Science his papers were cited 8300 times, with a Hirsch index of 43. He was also the principal investigator of more than 40 studies (e.g., Canadian-Cyclosporin Trial; Diapep277 Study; IDNT; IRMA 2; QUARTET; PROactive; GUIDE; ORIGIN; LEAD-6; DIRECT; EUREXA; DURATION; GENERATION).

Professor Schernthaner was awarded the Bertram Award of the German Diabetes Association in 1982 and the Albert Renold Medal of the European Association for the Study of Diabetes in 1997. He is currently the Liaison Editor for Diabetology for *Nephrology Dialysis Transplantation*.

*Dr Schernthaner reported no relevant financial relationships*

**Charles R V Tomson, DM, FRCP,** completed his undergraduate studies at Cambridge University and attended medical school at University of Oxford. Dr Tomson has worked as a Consultant Nephrologist at Southmead Hospital since April 1991. Between 1997 and 2004 he was course director for the Renal Association\'s Advanced Nephrology Course, and between 1998 and 2002 he was Secretary of the Renal Association\'s Audit and Standards Subcommittee, developing the 3rd edition of the Association\'s Standards document. In 2001 he set up and chaired the group that developed the first UK guidelines on identification, management and referral of patients with CKD. In 2004--5 he was a Health Foundation Quality Improvement Fellow at the Institute for Healthcare Improvement in Boston, USA. From 2006--2010 he was Chairman of the UK Renal Registry, which measures and reports on the quality of care achieved by all renal centers in the UK. He became President of the Renal Association in May 2010.

*Dr Tomson reported no relevant financial relationships*

**Carmine Zoccali, MD**, is Director of the Division of Nephrology, Hypertension and Renal Transplantation and Chief of the Clinical Epidemiology of Renal Diseases and Hypertension Unit of the National Research Council-IBIM at Riuniti Hospital, Calabria. He is Professor of Nephrology at the Postgraduate School of Nephrology, Universities of Palermo and Messina, Sicily, Italy. Having trained in medicine at the University of Rome, he completed specialist training in renal diseases, hypertension, internal medicine and clinical epidemiology.

Dr Zoccali\'s research interests cover hypertension, cardiovascular complications in chronic renal failure, kidney disease progression and the epidemiology of chronic renal failure. He has contributed over 600 publications in these areas, including more than 400 papers in international peer-reviewed journals with a Hirsch index of 52.

Dr Zoccali founded NDT-Educational in 2004 and directed its online educational resources between 2004--2009, and he is presently the Editor-in-Chief of *Nephrology Dialysis Transplantation*. Dr Zoccali also holds editorial positions in several national and international nephrology journals including *Clinical Nephrology*, *Clinical Journal of the American Society of Nephrology*, *Hypertension*, *Journal of the American Society of Nephrology*, *Journal of Hypertension*, *Journal of Nephrology, Kidney International*, *Nephron Clinical Practice*, and *PlosOne*. An ex-officio council member of the European Renal Association--European Dialysis and Transplant Association (ERA-EDTA), and of their selection committee, he is a member of numerous other nephrology societies. He was also Chairman of the European Dialysis and Transplant Registry (2003--2009), President of the Italian Society of Nephrology (2007--2008) and member of the KDIGO Board of Directors.

*Dr Zoccali reported no relevant financial relationships*

**KDIGO CHAIRS**

**Bertram L Kasiske, MD**, is Professor of Medicine at the University of Minnesota, USA. He received his medical degree from the University of Iowa and completed his Internal Medicine residency and fellowship training in Nephrology at Hennepin County Medical Center where he is currently Director of Nephrology.

Dr Kasiske is former Deputy Director of the United States Renal Data System and former Editor-in-Chief of *American Journal of Kidney Diseases*. He has served as Secretary/Treasurer and on the Board of Directors of the American Society of Transplantation, and on the Organ Procurement and Transplantation Network/United Network of Organ Sharing Board of Directors, and the Scientific Advisory Board of the US National Kidney Foundation. He is currently serving on the Board of Councilors of the International Society of Nephrology. He is the Principal Investigator for a National Institutes of Health-sponsored, multi-center study of long term outcomes after kidney donation and he is the Director of the Scientific Registry of Transplant Recipients. He has over 160 scientific publications in major peer reviewed journals, and 230 review articles, editorials and textbook chapters. Dr Kasiske is also a recipient of the US National Kidney Foundation\'s Garabed Eknoyan Award in 2003.

*Advisor/Consultant: Litholink*

*Grant/Research Support: Bristol-Myers Squibb; Merck (Schering Plough)*

**David C Wheeler, MD, FRCP** (see biography earlier)

**EVIDENCE REVIEW TEAM**

**Katrin Uhlig, MD, MS**, is the Director, Guideline Development at the Tufts Center for Kidney Disease Guideline Development and Implementation, Boston, MA, Associate Professor of Medicine at Tufts University School of Medicine, and a staff nephrologist at Tufts Medical Center. Dr Uhlig completed her training in internal medicine, nephrology, and rheumatology in Germany (Aachen University Hospital and Munich University Hospital) and the USA (Georgetown University Medical Center and Tufts Medical Center). Since 2001, she has been participating in or directing the evidence review for KDOQI and KDIGO guidelines. As Director of Guideline Development, Dr Uhlig has a substantial role in coordinating the ERT. She orchestrates and supervises the guideline development process and didactic curriculum that provides Work Group members with formal instruction on topics related to guideline development. As project director on individual guidelines, she directs and supervises the collection, evaluation, grading, and synthesis of evidence and the drafting and revisions of the final evidence report. She provides methodological guidance and training to Work Group members at meetings regarding topic refinement, key question formulation, data extraction, study assessment, evidence grading, and recommendation formulation. She provides nephrology expertise in the interpretation and review of guideline recommendations and evidence reports. In this capacity, Dr Uhlig possesses unique knowledge as a methods expert in evidence synthesis and critical literature appraisal in the domain of nephrology.

In 2005, she co-chaired the KDIGO Evidence Rating Group to develop a consensus on grading of KDIGO guidelines and also co-chaired the KDIGO Consensus Conference on Guideline Methodology in October 2007. From 2006 to 2007, she served as Co-Editor of *American Journal of Kidney Diseases*. Her teaching and research focus includes evidence-based medicine, systematic review, clinical practice guideline development, and critical literature appraisal. Dr Uhlig lectures on guideline topics and is a co-instructor of an annual course on meta-analysis in the Master of Science Program at the Sackler School of Graduate Biomedical Sciences at Tufts University.

*Dr Uhlig reported no relevant financial relationships*

**Ashish Upadhyay, MD**, is Assistant Professor, Renal Section and Associate Director, Internal Medicine Residency Program at Boston University School of Medicine, Boston, MA, USA. Dr Upadhyay was previously Assistant Professor at Tufts University School of Medicine and staff physician in the William B Schwartz, MD, Division of Nephrology at Tufts Medical Center. He joined the ERT in July 2009 and served as the Assistant Project Director for the *KDIGO Management of Blood Pressure in CKD* and *Anemia in CKD* Guidelines. Dr Upadhyay coordinated and assisted in the collection, evaluation, grading, and synthesis of evidence, and played a critical role in the revisions of the final evidence report. He also provided methodological guidance and training of Work Group members on topic refinement, key question formulation, data extraction, study assessment, evidence grading, and recommendation formulation. Dr Upadhyay\'s past research involved studying kidney disease epidemiology in the Framingham Heart Study. He has published in areas ranging from arterial stiffness in CKD and inflammation in kidney disease to dialysis complications and epidemiology of hyponatremia.

*Dr Upadhyay reported no relevant financial relationships*

**Amy Earley, BS**, is a project coordinator at the Tufts Center for Kidney Disease Guideline Development and Implementation in Boston, MA, USA. She is key in coordinating the guideline development activities within the ERT, especially in the development of the evidence reports for all guidelines. Ms Earley also heads the actual evidence review, which includes running searches, screening, data extraction, drafting of tables and methods sections, proofing of guideline drafts and critical literature appraisals. She participates in the conduct of research projects at the Center and actively collaborates with other members of the Center on independent research topics and manuscript submissions.

*Ms Earley reported no relevant financial relationships*

**Shana Haynes, MS, DHSc**, is a research assistant at the Tufts Center for Kidney Disease Guideline Development and Implementation in Boston, MA, USA. She participates in all aspects of evidence review and guideline development. She screens abstracts and articles, extracts data, and assists in the drafting and editing of evidence tables. Dr Haynes also assists in the development of clinical practice guidelines and conducts systematic reviews and critical literature appraisals.

*Dr Haynes reported no relevant financial relationships*

**Jenny Lamont, MS**, is a project manager and medical writer at the Tufts Center for Kidney Disease Guideline Development and Implementation in Boston, MA, USA. She participates in all aspects of evidence review and guideline development, assists in the preparation of talks and manuscripts, and edits KDIGO draft guidelines currently in progress.

*Ms Lamont reported no relevant financial relationships*
